Zealand Pharma A/S
ZEAL
Κατάταξη σε μετοχές
#5528
Zealand Pharma A/S is a Danish biotechnology firm dedicated to the... Zealand Pharma A/S is a Danish biotechnology firm dedicated to the identification, progression, and market introduction of peptide-based therapeutics. The company concentrates its efforts on treatments for gastrointestinal and metabolic ailments, as well as other specialized conditions where current medical options are insufficient. Its commercialized product, Dasiglucagon, is an injectable solution provided in a pre-filled syringe or autoinjector, used to address severe hypoglycemia. Furthermore, Zealand Pharma is actively developing Dasiglucagon for inclusion in bi-hormone artificial pancreas systems that integrate both insulin and dasiglucagon. The compound Dasiglucagon is also undergoing late-stage (Phase III) clinical trials for congenital hyperinsulinism. Another significant asset in its development pipeline is glepaglutide, a long-acting GLP-2 analog, which is likewise in Phase III clinical studies for treating short bowel syndrome. Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S maintains strategic alliances with a range of partners, including Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc.
Τιμή μετοχής
$34.57
Κεφαλαιοποίηση
$2.40B
Αλλαγή (1 ημέρα)
-0.99%
Αλλαγή (1 έτος)
-52.22%
Χώρα
DK
Εμπόριο Zealand Pharma A/S (ZEAL)
Κατηγορία
Healthcare
Ιστορικό τιμής μετοχής για την Zealand Pharma A/S (ZEAL)
Υψηλότερη τιμή κλεισίματος: $36.07 στις 2026-10-01
Χαμηλότερη τιμή κλεισίματος: $14.13 στις 2013-02-01
Χαμηλότερη τιμή κλεισίματος: $14.13 στις 2013-02-01
Ιστορικό τιμής μετοχής της Zealand Pharma A/S από 2013 έως 2026
Ετήσια απόδοση τιμής μετοχής
| Έτος | Απόδοση |
|---|---|
| 2026 (TTM) | -28.90% |
| 2025 | -27.05% |
| 2024 | 103.83% |
| 2023 | 83.97% |
| 2022 | 12.44% |
| 2021 | -30.48% |
| 2020 | 12.58% |
| 2019 | 163.90% |
| 2018 | -13.34% |
| 2017 | -14.27% |
| 2016 | -23.32% |
| 2015 | 66.31% |
| 2014 | 25.21% |
| 2013 | 0.00% |
Τιμή μετοχής για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Τιμή μετοχής | Μεταβολή 1Έτ% | Χώρα |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $760.15 | 8.04% |
CH
|
